These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 29123379

  • 1. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G, Panova E, Day R.
    Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
    [Abstract] [Full Text] [Related]

  • 2. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA.
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [Abstract] [Full Text] [Related]

  • 3. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED.
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.
    Arthritis Res Ther; 2019 Jan 07; 21(1):8. PubMed ID: 30616614
    [Abstract] [Full Text] [Related]

  • 5. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A.
    Ann Rheum Dis; 2017 May 07; 76(5):811-820. PubMed ID: 27821644
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S, RDEA594-111 Study Group.
    Rheumatology (Oxford); 2014 Dec 07; 53(12):2167-74. PubMed ID: 24509406
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW.
    Pharmacotherapy; 2018 Nov 07; 38(11):1106-1119. PubMed ID: 30246299
    [Abstract] [Full Text] [Related]

  • 8. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, Ito Y, Hall J.
    Rheumatology (Oxford); 2018 Sep 01; 57(9):1602-1610. PubMed ID: 29868853
    [Abstract] [Full Text] [Related]

  • 9. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S, Yeh LT, Shen Z, Kerr B, Manhard K, Quart B.
    J Clin Pharmacol; 2018 Sep 01; 58(9):1164-1170. PubMed ID: 29733441
    [Abstract] [Full Text] [Related]

  • 10. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.
    Arthritis Rheumatol; 2017 Sep 01; 69(9):1903-1913. PubMed ID: 28597604
    [Abstract] [Full Text] [Related]

  • 11. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
    Jansen TL, Perez-Ruiz F, Tausche AK, Richette P.
    Clin Rheumatol; 2018 Dec 01; 37(12):3159-3165. PubMed ID: 30244431
    [Abstract] [Full Text] [Related]

  • 12. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N, Sun M, Sun R, Xu T, Cui L, Wang C, Ma L, Cheng X, Xue X, Sun W, Yuan X, Zhang H, Li H, He Y, Ji A, Wu X, Li C.
    Arthritis Res Ther; 2019 Sep 02; 21(1):200. PubMed ID: 31477161
    [Abstract] [Full Text] [Related]

  • 13. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
    Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.
    Rheumatology (Oxford); 2017 Dec 01; 56(12):2170-2178. PubMed ID: 29029210
    [Abstract] [Full Text] [Related]

  • 14. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
    Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, RDEA594-203 Study Group.
    Ann Rheum Dis; 2016 Jun 01; 75(6):1074-80. PubMed ID: 26742777
    [Abstract] [Full Text] [Related]

  • 15. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B.
    Arthritis Res Ther; 2016 Oct 03; 18(1):214. PubMed ID: 27716403
    [Abstract] [Full Text] [Related]

  • 16. New urate-lowing therapies.
    Abhishek A.
    Curr Opin Rheumatol; 2018 Mar 03; 30(2):177-182. PubMed ID: 29251661
    [Abstract] [Full Text] [Related]

  • 17. Uricosuric medications for chronic gout.
    Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C.
    Cochrane Database Syst Rev; 2014 Nov 14; 2014(11):CD010457. PubMed ID: 25392987
    [Abstract] [Full Text] [Related]

  • 18. Lesinurad: A Novel Agent for Management of Chronic Gout.
    Haber SL, Fente G, Fenton SN, Walker EP, Weaver BM, Cano AJ, Vu K.
    Ann Pharmacother; 2018 Jul 14; 52(7):690-696. PubMed ID: 29482353
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Kerr B.
    Clin Pharmacol Drug Dev; 2017 Jul 14; 6(4):377-387. PubMed ID: 28074640
    [Abstract] [Full Text] [Related]

  • 20. Lesinurad for the treatment of hyperuricaemia in people with gout.
    Robinson PC, Dalbeth N.
    Expert Opin Pharmacother; 2017 Dec 14; 18(17):1875-1881. PubMed ID: 29103339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.